These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 32382656)
1. miR-124 Intensified Oxaliplatin-Based Chemotherapy by Targeting CAPN2 in Colorectal Cancer. Xie XQ; Wang MJ; Li Y; Lei LP; Wang N; Lv ZY; Chen KL; Zhou B; Ping J; Zhou ZG; Sun XF Mol Ther Oncolytics; 2020 Jun; 17():320-331. PubMed ID: 32382656 [TBL] [Abstract][Full Text] [Related]
2. Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway. Wei Z; Zhou J; Yu H; Pu Y; Cheng Y; Zhang Y; Ji Q; Zhu H Evid Based Complement Alternat Med; 2022; 2022():3032407. PubMed ID: 36248422 [TBL] [Abstract][Full Text] [Related]
3. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer. Yao Y; Zhao H; Sun Y; Lin F; Tang L; Chen P Tohoku J Exp Med; 2008 Jul; 215(3):267-78. PubMed ID: 18648187 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy. Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S Oncol Rep; 2016 Dec; 36(6):3682-3690. PubMed ID: 27779719 [TBL] [Abstract][Full Text] [Related]
5. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells. Tanaka S; Hosokawa M; Yonezawa T; Hayashi W; Ueda K; Iwakawa S Biol Pharm Bull; 2015; 38(3):435-40. PubMed ID: 25757925 [TBL] [Abstract][Full Text] [Related]
6. Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells. Suzuki S; Tanigawara Y Proteome Sci; 2014; 12():26. PubMed ID: 24851084 [TBL] [Abstract][Full Text] [Related]
7. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX. Hu J; Cai G; Xu Y; Cai S Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693 [TBL] [Abstract][Full Text] [Related]
8. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242 [TBL] [Abstract][Full Text] [Related]
9. Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test. Ochiai T; Nishimura K; Watanabe T; Kitajima M; Hashiguchi T; Nakatani A; Marusasa T; Muraki A; Nagaoka I; Futagawa S Exp Ther Med; 2010 Mar; 1(2):325-329. PubMed ID: 22993545 [TBL] [Abstract][Full Text] [Related]
10. Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway. Liang Y; Zhu D; Zhu L; Hou Y; Hou L; Huang X; Li L; Wang Y; Li L; Zou H; Wu T; Yao M; Wang J; Meng X J Cancer; 2019; 10(24):6037-6047. PubMed ID: 31762813 [TBL] [Abstract][Full Text] [Related]
11. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer. Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Li PL; Zhang X; Wang LL; Du LT; Yang YM; Li J; Wang CX Carcinogenesis; 2015 Dec; 36(12):1484-93. PubMed ID: 26442524 [TBL] [Abstract][Full Text] [Related]
14. The Effect of Compound Yin W; Zhong G; Fan H; Xia H Evid Based Complement Alternat Med; 2019; 2019():7564232. PubMed ID: 31949471 [TBL] [Abstract][Full Text] [Related]
15. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355 [TBL] [Abstract][Full Text] [Related]
16. miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells. Tanaka S; Hosokawa M; Miyamoto T; Nakagawa A; Haruna M; Ueda K; Iwakawa S; Ogawara KI Biochem Biophys Rep; 2021 Jul; 26():100996. PubMed ID: 33898768 [TBL] [Abstract][Full Text] [Related]
17. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity. Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111 [TBL] [Abstract][Full Text] [Related]
18. Suppression of GRP78 sensitizes human colorectal cancer cells to oxaliplatin by downregulation of CD24. Xi J; Chen Y; Huang S; Cui F; Wang X Oncol Lett; 2018 Jun; 15(6):9861-9867. PubMed ID: 29805687 [TBL] [Abstract][Full Text] [Related]
19. Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression. Song Y; Kang Y; Lin Z; Zeng M; Shi P; Lin J; Lu P; Luo L; Cao Y; Zhu X J Cancer; 2021; 12(7):1952-1959. PubMed ID: 33753993 [TBL] [Abstract][Full Text] [Related]
20. Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil. Liu A; Qiao J; He L; Liu Z; Chen J; Pei F; Du Y Onco Targets Ther; 2019; 12():8637-8644. PubMed ID: 31695423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]